Metal homeostasis in Alzheimer’s disease

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Expert Review of Neurotherapeutics

• Publication date

  2006-05-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1586/14737175.6.5.711PMID 16734519
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Iron in the brain.

  2009cited by this paper
• Characterization of copper interactions with alzheimer amyloid beta peptides: identification of an attomolar-affinity copper binding site on amyloid beta1-42.

  2008cited by this paper
• Commentary on “Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice”

  2006cited by this paper
• Synchrotron-based infrared and X-ray imaging shows focalized accumulation of Cu and Zn co-localized with beta-amyloid deposits in Alzheimer's disease.

  2006cited by this paper
• Degradation of the Alzheimer Disease Amyloid β-Peptide by Metal-dependent Up-regulation of Metalloprotease Activity*

  2006cited by this paper
• Metals, toxicity and oxidative stress.

  2005cited by this paper
• Nanoparticle and other metal chelation therapeutics in Alzheimer disease.

  2005cited by this paper
• The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy

  2005cited by this paper
• Methylation of the Imidazole Side Chains of the Alzheimer Disease Amyloid-β Peptide Results in Abolition of Superoxide Dismutase-like Structures and Inhibition of Neurotoxicity*

  2005cited by this paper
• Association of homocysteine with plasma amyloid β protein in aging and neurodegenerative disease

  2005cited by this paper
• Copper-Dependent Inhibition of Human Cytochrome c Oxidase by a Dimeric Conformer of Amyloid-β1-42

  2005cited by this paper
• Alzheimer disease beta-amyloid activity mimics cholesterol oxidase.

  2005cited by this paper
• Metals and amyloid‐β in Alzheimer's disease

  2005cited by this paper
• Promotion of Oxidative Lipid Membrane Damage by Amyloid β Proteins

  2005cited by this paper
• Promotion of oxidative lipid membrane damage by amyloid beta proteins.

  2005cited by this paper
• Cognitive decline correlates with low plasma concentrations of copper in patients with mild to moderate Alzheimer's disease

  2005cited by this paper
• Association of homocysteine with plasma amyloid beta protein in aging and neurodegenerative disease.

  2005cited by this paper
• Alzheimer disease β-amyloid activity mimics cholesterol oxidase

  2005cited by this paper
• Metal-protein attenuating compounds and Alzheimer’s disease

  2004cited by this paper
• Enhanced Toxicity and Cellular Binding of a Modified Amyloid β Peptide with a Methionine to Valine Substitution*

  2004cited by this paper
• The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human beta-amyloid precursor protein transgenic mice.

  2004cited by this paper
• Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer's disease β‐amyloid

  2004cited by this paper
• Copper mediates dityrosine cross-linking of Alzheimer's amyloid-beta.

  2004cited by this paper
• Gene knockout of amyloid precursor protein and amyloid precursor‐like protein‐2 increases cellular copper levels in primary mouse cortical neurons and embryonic fibroblasts

  2004cited by this paper
• Neuronal Zinc Exchange with the Blood Vessel Wall Promotes Cerebral Amyloid Angiopathy in an Animal Model of Alzheimer's Disease

  2004cited by this paper
• In vivo reduction of amyloid-β by a mutant copper transporter

  2003cited by this paper
• Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence.

  2003cited by this paper
• The metallobiology of Alzheimer's disease.

  2003cited by this paper
• Adventiously-bound redox active iron and copper are at the center of oxidative damage in Alzheimer disease

  2003cited by this paper
• Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial.

  2003cited by this paper
• In vivo reduction of amyloid-beta by a mutant copper transporter.

  2003cited by this paper
• Structure and evolutionary aspects of matrix metalloproteinases: A brief overview

  2003cited by this paper
• Neurotoxic, Redox-competent Alzheimer's β-Amyloid Is Released from Lipid Membrane by Methionine Oxidation*

  2003cited by this paper
• Structure of the Alzheimer's Disease Amyloid Precursor Protein Copper Binding Domain

  2003cited by this paper
• Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid Aβ production in APP23 transgenic mice

  2003cited by this paper
• An Iron-responsive Element Type II in the 5′-Untranslated Region of the Alzheimer's Amyloid Precursor Protein Transcript*

  2002cited by this paper
• Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice

  2002cited by this paper
• β‐Amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases?

  2002cited by this paper
• Human alpha-fetoprotein as a Zn(2+)-binding protein. Tight cation binding is not accompanied by global changes in protein structure and stability.

  2002cited by this paper
• Novel therapeutic strategies provide the real test for the amyloid hypothesis of Alzheimer's disease.

  2002cited by this paper
• Contrasting, Species-Dependent Modulation of Copper-Mediated Neurotoxicity by the Alzheimer's Disease Amyloid Precursor Protein

  2002cited by this paper
• Overexpression of Alzheimer's Disease Amyloid-β Opposes the Age-dependent Elevations of Brain Copper and Iron*

  2002cited by this paper
• Human α-fetoprotein as a Zn2+-binding protein. Tight cation binding is not accompanied by global changes in protein structure and stability

  2002cited by this paper
• Alzheimer Disease and Oxidative Stress

  2002cited by this paper
• Role of glycine-33 and methionine-35 in Alzheimer's amyloid beta-peptide 1-42-associated oxidative stress and neurotoxicity.

  2002cited by this paper
• Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2).

  2002cited by this paper
• Brain Iron Metabolism and Neurodegenerative Disorders

  2002cited by this paper
• Metallothionein III is reduced in Alzheimer's disease.

  2001cited by this paper
• Iron on the brain

  2001cited by this paper
• On the structural form of iron in ferritin cores associated with progressive supranuclear palsy and Alzheimer's disease.

  2001cited by this paper
• Alzheimer's disease: genes, proteins, and therapy.

  2001cited by this paper
• Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits β-Amyloid Accumulation in Alzheimer's Disease Transgenic Mice

  2001cited by this paper
• Inhibitory effect of copper(II) on zinc(II)-induced aggregation of amyloid beta-peptide.

  2001cited by this paper
• Homocysteine potentiates copper‐ and amyloid beta peptide‐mediated toxicity in primary neuronal cultures: possible risk factors in the Alzheimer's‐type neurodegenerative pathways

  2001cited by this paper
• Mitochondrial enzyme-deficient hippocampal neurons and choroidal cells in AD

  2001cited by this paper
• Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes

  2001cited by this paper
• Redox-active iron mediates amyloid-beta toxicity.

  2001cited by this paper
• Iron and iron management proteins in neurobiology.

  2001cited by this paper
• Alzheimer's Disease Amyloid-β Binds Copper and Zinc to Generate an Allosterically Ordered Membrane-penetrating Structure Containing Superoxide Dismutase-like Subunits*

  2001cited by this paper
• Redox-active iron mediates amyloid-β toxicity

  2001cited by this paper
• The a-Macroglobulin Bait Region SEQUENCE DIVERSITY AND LOCALIZATION OF CLEAVAGE SITES FOR PROTEINASES IN FIVE MAMMALIAN a-MACROGLOBULINS*

  2001cited by this paper
• Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice.

  2001cited by this paper
• Copper catalyzed oxidation of Alzheimer Abeta.

  2000cited by this paper
• Importance of zinc in the central nervous system: the zinc-containing neuron.

  2000cited by this paper
• Heme oxygenase-1: role in brain aging and neurodegeneration.

  2000cited by this paper
• In Situ Oxidative Catalysis by Neurofibrillary Tangles and Senile Plaques in Alzheimer’s Disease

  2000cited by this paper
• Zn(2+): a novel ionic mediator of neural injury in brain disease.

  2000cited by this paper
• Characterization of Copper Interactions with Alzheimer Amyloid β Peptides

  2000cited by this paper
• Movement of zinc and its functional significance in the brain.

  2000cited by this paper
• Evidence that the β-Amyloid Plaques of Alzheimer's Disease Represent the Redox-silencing and Entombment of Aβ by Zinc*

  2000cited by this paper
• Metal Chelation as a Potential Therapy for Alzheimer's Disease

  2000cited by this paper
• Evidence that the beta-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of abeta by zinc.

  2000cited by this paper
• A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients.

  2000cited by this paper
• The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction.

  1999cited by this paper
• Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease

  1999cited by this paper
• Histidine-13 is a crucial residue in the zinc ion-induced aggregation of the A beta peptide of Alzheimer's disease.

  1999cited by this paper
• Exacerbation of Copper Toxicity in Primary Neuronal Cultures Depleted of Cellular Glutathione

  1999cited by this paper
• Histochemically Reactive Zinc in Plaques of the Swedish Mutant β-Amyloid Precursor Protein Transgenic Mice

  1999cited by this paper
• Aqueous Dissolution of Alzheimer’s Disease Aβ Amyloid Deposits by Biometal Depletion*

  1999cited by this paper
• Copper inhibits beta-amyloid production and stimulates the non-amyloidogenic pathway of amyloid-precursor-protein secretion.

  1999cited by this paper
• The Alzheimer's Disease Amyloid Precursor Protein Modulates Copper-Induced Toxicity and Oxidative Stress in Primary Neuronal Cultures

  1999cited by this paper
• Role of free radicals and metal ions in the pathogenesis of Alzheimer's disease.

  1999cited by this paper
• It all sticks together—the APP-related family of proteins and Alzheimer's disease

  1999cited by this paper
• In vitro peroxidase oxidation induces stable dimers of beta-amyloid (1-42) through dityrosine bridge formation.

  1999cited by this paper
• Undetectable intracellular free copper: the requirement of a copper chaperone for superoxide dismutase.

  1999cited by this paper
• Copper levels are increased in the cerebral cortex and liver of APP and APLP2 knockout mice.

  1999cited by this paper
• Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction.

  1999cited by this paper
• Copper, iron and zinc in Alzheimer's disease senile plaques.

  1998cited by this paper
• α2‐Macroglobulin Attenuates β‐Amyloid Peptide 1–40 Fibril Formation and Associated Neurotoxicity of Cultured Fetal Rat Cortical Neurons

  1998cited by this paper
• Metallothioneins are highly expressed in astrocytes and microcapillaries in Alzheimer's disease.

  1998cited by this paper
• Alpha2-macroglobulin attenuates beta-amyloid peptide 1-40 fibril formation and associated neurotoxicity of cultured fetal rat cortical neurons.

  1998cited by this paper
• Alzheimer's disease

  1998cited by this paper
• Irreversible dimerization/tetramerization and post-translational modifications inhibit proteolytic degradation of A beta peptides of Alzheimer's disease.

  1998cited by this paper
• Dramatic Aggregation of Alzheimer Aβ by Cu(II) Is Induced by Conditions Representing Physiological Acidosis*

  1998cited by this paper
• Zinc metabolism in the brain: relevance to human neurodegenerative disorders.

  1997cited by this paper
• Widespread Peroxynitrite-Mediated Damage in Alzheimer’s Disease

  1997cited by this paper
• α2‐Macroglobulin as a β‐Amyloid Peptide‐Binding Plasma Protein

  1997cited by this paper
• alpha2-Macroglobulin as a beta-amyloid peptide-binding plasma protein.

  1997cited by this paper
• Zinc-induced Alzheimer’s Aβ1–40 Aggregation Is Mediated by Conformational Factors*

  1997cited by this paper
• Iron accumulation in Alzheimer disease is a source of redox-generated free radicals.

  1997cited by this paper

• Cuproptosis: mechanisms and links with Alzheimer's Disease.

  2025cites this paper
• Dual-action peptide shuttles rescue Cu-amyloid-β-induced neurotoxicity and relocate Cu intracellularly

  2025cites this paper
• Investigation of the concentration and isotopic composition of Cu, Fe and Zn in human biofluids in the context of Alzheimer's disease via tandem and multi-collector inductively coupled plasma-mass spectrometry.

  2024cites this paper
• Metal ion mediated aggregation of Alzheimer's disease peptides and proteins in solutions and at surfaces.

  2023cites this paper
• Blood-brain barrier dysfunction as a potential therapeutic target for neurodegenerative disorders

  2021cites this paper
• Targeting Endothelin in Alzheimer's Disease: A Promising Therapeutic Approach

  2021cites this paper
• Oxidative Stress in Alzheimer’s Disease: Molecular Hallmarks of Underlying Vulnerability

  2019cites this paper
• Development of novel theranostic agents for in vivo amyloid imaging and protective effects on human neuroblastoma cells.

  2019cites this paper
• Advances in Multi-Functional Ligands and the Need for Metal-Related Pharmacology for the Management of Alzheimer Disease

  2018cites this paper
• The double-edged role of copper in the fate of amyloid beta in the presence of anti-oxidants† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c7sc01787a Click here for additional data file.

  2017cites this paper
• Design, Synthesis and Biological Evaluation of Novel Adamantane Derivatives as Potential Treatments for Alzheimer’s Disease

  2017cites this paper
• Fluorescent Copper Probe Inhibiting Aβ1-16-Copper(II)-Catalyzed Intracellular Reactive Oxygen Species Production.

  2017cites this paper
• Hybrid Antioxidant and Metal Sequestering Small Molecules Targeting the Molecular Features of Alzheimer’s Disease

  2017cites this paper
• Copper and Alzheimer's Disease.

  2017cites this paper
• Intracellular Bioinorganic Chemistry and Cross Talk Among Different -Omics.

  2016cites this paper
• Profound Morphological Changes in the Erythrocytes and Fibrin Networks of Patients with Hemochromatosis or with Hyperferritinemia, and Their Normalization by Iron Chelators and Other Agents

  2014cites this paper
• Drug-like chelating agents: a potential lead for Alzheimer's disease

  2014cites this paper
• The tachykinin peptide neurokinin B binds copper(I) and silver(I) and undergoes quasi-reversible electrochemistry: towards a new function for the peptide in the brain.

  2014cites this paper
• Pharmacogenomics in Drug Discovery and Development

  2014cites this paper
• Elevated copper in the amyloid plaques and iron in the cortex are observed in mouse models of Alzheimer's disease that exhibit neurodegeneration

  2013cites this paper
• Metallostasis in Alzheimer's disease.

  2013cites this paper
• Design and synthesis of curcumin analogues for in vivo fluorescence imaging and inhibiting copper-induced cross-linking of amyloid beta species in Alzheimer's disease.

  2013cites this paper
• The inorganic perspectives of neurotrophins and Alzheimer's disease.

  2012cites this paper
• Effects of a Copper-Deficient Diet on the Biochemistry, Neural Morphology and Behavior of Aged Mice

  2012cites this paper
• Transgenic mice as a model for Alzheimer's disease.

  2011cites this paper
• Increased brain iron coincides with early plaque formation in a mouse model of Alzheimer's disease

  2011cites this paper
• Animal Models of Metallic Dementia

  2011cites this paper
• Small molecule inhibitors of Aβ‐aggregation and neurotoxicity

  2009cites this paper
• Amyloid plaques in PSAPP mice bind less metal than plaques in human Alzheimer's disease

  2009cites this paper
• Nicotinic Acetylcholine Receptors in Alzheimer ’ s Disease-related Mouse Models-Interactive Mechanisms with Focus on New Drug Targets

  2009cites this paper
• Bimodal modulation of tau protein phosphorylation and conformation by extracellular Zn2+ in human-tau transfected cells.

  2009cites this paper
• Oxidative stress in Alzheimer disease

  2009cites this paper
• Clioquinol and other hydroxyquinoline derivatives inhibit Abeta(1-42) oligomer assembly.

  2009cites this paper
• Pharmacogenomics in Alzheimer's disease.

  2008cites this paper
• The role of metals in modulating metalloprotease activity in the AD brain

  2008cites this paper
• Transgenic mice overexpressing human acetylcholinesterase and the Swedish amyloid precursor protein mutation: effect of nicotine treatment.

  2008cites this paper
• Chelation of neurotoxic zinc levels does not improve neurobehavioral outcome after traumatic brain injury.

  2008cites this paper
• The metal loading ability of beta-amyloid N-terminus: a combined potentiometric and spectroscopic study of copper(II) complexes with beta-amyloid(1-16), its short or mutated peptide fragments, and its polyethylene glycol (PEG)-ylated analogue.

  2008cites this paper
• Multi-target-directed ligands to combat neurodegenerative diseases.

  2008cites this paper
• Neurotoxicity from glutathione depletion is mediated by Cu-dependent p53 activation.

  2008cites this paper
• Aβ(25–35) and its C‐ and/or N‐blocked derivatives: Copper driven structural features and neurotoxicity

  2007cites this paper
• Role of the APP non-amyloidogenic signaling pathway and targeting alpha-secretase as an alternative drug target for treatment of Alzheimer's disease.

  2007cites this paper
• Cell-replacement and gene-therapy strategies for Parkinson's and Alzheimer's disease.

  2007cites this paper
• Fluorescent molecular sensors and multi-photon microscopy in brain studies.

  2007cites this paper
• Copper and Alzheimer's disease

  1996cites this paper